Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment